{
  "pmcid": "12448043",
  "sha256": "97b160137e12c2f9beabaeecb185e230c5a4cca0e9b1d915e1446318fc73ecd4",
  "timestamp_utc": "2025-11-09T15:42:27.729920+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 18.085151515151512,
    "reading_ease": 8.147727272727309,
    "word_count": 264
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "A rotational thromboelastometry (ROTEM ® ) guided transfusion strategy for obstetrics was implemented at our institution in September 2022."
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "944 women who experienced postpartum haemorrhage ≥ 1500 ml over a 5‐year period"
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing 1 year of data after the formal introduction of the ROTEM ® ‐guided transfusion strategy (post‐ROTEM ® ) with the previous 4 years, when a conventional transfusion strategy was in place based on standard laboratory tests (pre‐ROTEM ® )."
      },
      "Objective": {
        "score": 1,
        "evidence": "The aim of the strategy was to facilitate timely, targeted administration of coagulation products based on viscoelastic haemostatic testing, thereby reducing unnecessary transfusions."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "97/238 (40%) in the post‐ROTEM ® group vs. 312/706 (44%) in the pre‐ROTEM group"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Following implementation, the annual use of fibrinogen concentrate, Octaplas ® (Octapharma Pharmazeutika GmbH, Vienna, Austria) and platelets to treat PPH ≥ 1500 ml decreased by 46%, 72% and 79%, respectively, yielding a cost saving of €51,738."
      },
      "Harms": {
        "score": 1,
        "evidence": "There was no statistically significant difference in the proportion of women who progressed to severe haemorrhage (≥ 2000 ml) between groups: 97/238 (40%) in the post‐ROTEM ® group vs. 312/706 (44%) in the pre‐ROTEM group (p = 0.35)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  }
}